From Computer Tyme Support Wiki

Revision as of 17:02, 4 May 2017

My Immune Therapy Plan

Nivolumab (Opdivo) and other immunotherapy drugs work by both boosting the immune system and targeting cancer using "checkpoint inhibitors". Some cancers put put a substance called PD-L1 that makes the adaptive immune system (T Cells) not be able to see the cancer. PD-L1 is an "I'm a friend - don't kill me" signal that hides the cancer from attack. Opdivo removes the mask allowing the immune system to see the cancer and attack it. In some cases even leading to a complete cure.

However ...

You can't unmask something that isn't masked in the first place so if you have PD-L1 then that's great. But I don't have it so a drug that removes a mask that isn't there isn't likely to work.

Nivolumab apparently does more that just remove the mask. Although the literature focuses on PD-L1, the list of possible side effects look similar to people who have autoimmune problems. In other words - it looks like it also stimulates the immune system to the point where it might attack your body's good cells. It appears that Nivolumab has more than one function - to unmask the cancer - and to stimulate the immune system and put it in learn mode so that the T cells can identify the cancer and attack it.